{"success":true,"data":{"pressRelease":{"id":"61832","rtpr_id":"nGNX7Kjm6L","ticker":"ZBIO","exchange":"NASDAQ","all_tickers":["ZBIO"],"title":"Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit","author":"Globe Newswire","published_at":"2026-06-11T20:15:00.098Z","article_body":"WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.\n(“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a\nclinical-stage global biopharmaceutical company committed to being a leader in\nthe development and commercialization of transformative therapies for patients\nliving with autoimmune diseases, today announced management’s presentation\nat the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The\npresentation will be available on-demand beginning on Monday, June 15, 2026,\nat 7:00 a.m. ET.\n\nA webcast and archived replay of the Company’s presentation can be accessed\nunder “Events and Presentations” in the Investor & Media Relations\n(https://www.globenewswire.com/Tracker?data=V1tzjYyqf9-65MwjBufkNmSu5KE08Gz8Mh08e3S2ZqtSdJuzgEabywo1kJ_BntZJ52_Ij7Xx9SMoStZsh2UiT2yaw6S7SrwihJxqmFJfSHiZROK7NyfUlNbAUgspTJJ_)\nsection of the Zenas BioPharma website\n(https://www.globenewswire.com/Tracker?data=_j6rIAt0Icke0rorqMJILSp2IHA810MCzJaux7I65sEhFRp5M4cDOh-FMZ14FEBcSCSRKR8uOy8sN0xJWuyN2A==).\n\nAbout Zenas BioPharma, Inc.\nZenas is a clinical-stage global biopharmaceutical company committed to\nbecoming a leader in the development and commercialization of transformative\ntherapies for patients living with autoimmune diseases. Zenas’ core business\nstrategy combines our experienced leadership team with a disciplined product\ncandidate acquisition approach to identify, acquire and develop product\ncandidates globally that we believe can provide superior clinical benefits to\npatients living with autoimmune diseases. Zenas is advancing two late-stage,\npotential franchise molecules, obexelimab and orelabrutinib. Obexelimab,\nZenas’ lead product candidate, is a bifunctional monoclonal antibody\ndesigned to bind both CD19 and FcγRIIb, which are broadly present across B\ncell lineage, to inhibit the activity of cells that are implicated in many\nautoimmune diseases without depleting them. Zenas believes that the unique\nmechanism of action of obexelimab and its self-administered, subcutaneous\ninjection regimen may broadly and effectively address the pathogenic role of B\ncell lineage in chronic autoimmune disease. Orelabrutinib is a potentially\nbest-in-class, highly selective CNS-penetrant, oral, small molecule BTK\ninhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells\nnot only in the periphery but also within the CNS. Additionally, it directly\nmodulates macrophages and microglial cells in the CNS, with the potential to\naddress compartmentalized inflammation and disease progression in MS. Zenas’\nearlier stage programs include ZB021, a novel, potentially best-in-class, oral\nsmall molecule IL-17AA/AF inhibitor, ZB022, a preclinical, potentially\nbest-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a\npreclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody.\nFor more information about Zenas BioPharma, please\nvisit https://zenasbio.com/ and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=OOCOvUz0X-WNmdO-nXsjYeY3t2dEOr2bVJ99ylegvg0ORRVir4Ldye1gxPEGpboNZiYM7pKqRvroZUIVRbHRIQQZSVVSMJy8gYGfGLR3FPEG2J75aZbA-Byjhf5pcQivItsM0HV-rASVvSyyyrLjcWME99uVmhcK8e8bMEe9zBAi9a3F0rH5Qxn1h2jvqZu0FXHbNME9N6cOsgq2gPYr1rN8li4tmvwz_sFY12GEFcP5jveGNHaYpdig8SVszQaZmR_DSZcicmBGh6jL75tRO50i7QwBQQjEoICiTNQfsoKYrKhRYoF1LcLsY5pgn6g2).\n\nThe Zenas BioPharma word mark, logo mark, and the “lightning bolt” design\nare trademarks of Zenas BioPharma, Inc. or its affiliated companies.\n\nInvestor and Media Contact:\nArgot Partners\nZenas@argotpartners.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/11a7c081-eaf9-4e1d-b413-227c20d8d41a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7Kjm6L","title":"Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit","author":"Globe Newswire","ticker":"ZBIO","created":"2026-06-11T20:15:00.098Z","tickers":["ZBIO"],"exchange":"NASDAQ","article_body":"WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.\n(“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a\nclinical-stage global biopharmaceutical company committed to being a leader in\nthe development and commercialization of transformative therapies for patients\nliving with autoimmune diseases, today announced management’s presentation\nat the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The\npresentation will be available on-demand beginning on Monday, June 15, 2026,\nat 7:00 a.m. ET.\n\nA webcast and archived replay of the Company’s presentation can be accessed\nunder “Events and Presentations” in the Investor & Media Relations\n(https://www.globenewswire.com/Tracker?data=V1tzjYyqf9-65MwjBufkNmSu5KE08Gz8Mh08e3S2ZqtSdJuzgEabywo1kJ_BntZJ52_Ij7Xx9SMoStZsh2UiT2yaw6S7SrwihJxqmFJfSHiZROK7NyfUlNbAUgspTJJ_)\nsection of the Zenas BioPharma website\n(https://www.globenewswire.com/Tracker?data=_j6rIAt0Icke0rorqMJILSp2IHA810MCzJaux7I65sEhFRp5M4cDOh-FMZ14FEBcSCSRKR8uOy8sN0xJWuyN2A==).\n\nAbout Zenas BioPharma, Inc.\nZenas is a clinical-stage global biopharmaceutical company committed to\nbecoming a leader in the development and commercialization of transformative\ntherapies for patients living with autoimmune diseases. Zenas’ core business\nstrategy combines our experienced leadership team with a disciplined product\ncandidate acquisition approach to identify, acquire and develop product\ncandidates globally that we believe can provide superior clinical benefits to\npatients living with autoimmune diseases. Zenas is advancing two late-stage,\npotential franchise molecules, obexelimab and orelabrutinib. Obexelimab,\nZenas’ lead product candidate, is a bifunctional monoclonal antibody\ndesigned to bind both CD19 and FcγRIIb, which are broadly present across B\ncell lineage, to inhibit the activity of cells that are implicated in many\nautoimmune diseases without depleting them. Zenas believes that the unique\nmechanism of action of obexelimab and its self-administered, subcutaneous\ninjection regimen may broadly and effectively address the pathogenic role of B\ncell lineage in chronic autoimmune disease. Orelabrutinib is a potentially\nbest-in-class, highly selective CNS-penetrant, oral, small molecule BTK\ninhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells\nnot only in the periphery but also within the CNS. Additionally, it directly\nmodulates macrophages and microglial cells in the CNS, with the potential to\naddress compartmentalized inflammation and disease progression in MS. Zenas’\nearlier stage programs include ZB021, a novel, potentially best-in-class, oral\nsmall molecule IL-17AA/AF inhibitor, ZB022, a preclinical, potentially\nbest-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a\npreclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody.\nFor more information about Zenas BioPharma, please\nvisit https://zenasbio.com/ and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=OOCOvUz0X-WNmdO-nXsjYeY3t2dEOr2bVJ99ylegvg0ORRVir4Ldye1gxPEGpboNZiYM7pKqRvroZUIVRbHRIQQZSVVSMJy8gYGfGLR3FPEG2J75aZbA-Byjhf5pcQivItsM0HV-rASVvSyyyrLjcWME99uVmhcK8e8bMEe9zBAi9a3F0rH5Qxn1h2jvqZu0FXHbNME9N6cOsgq2gPYr1rN8li4tmvwz_sFY12GEFcP5jveGNHaYpdig8SVszQaZmR_DSZcicmBGh6jL75tRO50i7QwBQQjEoICiTNQfsoKYrKhRYoF1LcLsY5pgn6g2).\n\nThe Zenas BioPharma word mark, logo mark, and the “lightning bolt” design\nare trademarks of Zenas BioPharma, Inc. or its affiliated companies.\n\nInvestor and Media Contact:\nArgot Partners\nZenas@argotpartners.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/11a7c081-eaf9-4e1d-b413-227c20d8d41a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-11T20:15:00.144425704Z","server_sent_at_ms":1781208900144},"received_at":"2026-06-11T20:15:00.204Z","source_url":null},"analysis":{"id":"51257","press_release_id":"61832","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.\n\nThe presentation will be available on-demand starting June 15, 2026, at 7:00 a.m. ET.\n\nNo new clinical data or regulatory milestones were disclosed in this announcement.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference presentation -- low signal for downstream automation."},"keyFigures":{},"quotedText":"Zenas BioPharma, Inc. ... today announced management’s presentation at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.","namedEntities":{"people":[],"products":["obexelimab","orelabrutinib","ZB021","ZB022","ZB014"],"companies":[{"name":"Zenas BioPharma, Inc.","ticker":"ZBIO","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference organizer"},{"name":"Argot Partners","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference presentation announcement with no new clinical data, regulatory updates, or financial disclosures. Standard investor relations activity for a clinical-stage biotech."},"tickerRelevance":{"others":[],"primary":"ZBIO"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_ir_activity","sectorWeight":"biotech","householdBrandBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.\n\nThe presentation will be available on-demand starting June 15, 2026, at 7:00 a.m. ET.\n\nNo new clinical data or regulatory milestones were disclosed in this announcement.","key_figures":{},"named_entities":{"people":[],"products":["obexelimab","orelabrutinib","ZB021","ZB022","ZB014"],"companies":[{"name":"Zenas BioPharma, Inc.","ticker":"ZBIO","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference organizer"},{"name":"Argot Partners","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-11T20:15:21.368Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_ir_activity","sectorWeight":"biotech","householdBrandBoost":0}},"durationMs":21161,"modelName":"george-droid-qwen-72b"}}